Group 1 - MAIA Biotechnology, Inc. has entered into definitive agreements for the purchase and sale of 1,233,488 shares of common stock at a price of $1.224 per share in a private placement to accredited investors and a Company director [1] - Each share is offered with a warrant to purchase one additional share at an exercise price of $1.36, with the warrants exercisable six months after issuance and valid for three years [1] - The private placement is expected to close on or about December 18, 2025, subject to customary closing conditions [1] Group 2 - The gross proceeds from the offering are expected to be approximately $1.51 million before offering expenses [2] - The net proceeds will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for working capital [2] Group 3 - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws [3] - The warrants and underlying shares may not be offered or sold in the United States except under an effective registration statement or applicable exemption [3] Group 4 - MAIA is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5]

Core Viewpoint - MAIA Biotechnology, Inc. has announced a private placement of 1,733,766 shares of common stock at a price of $1.30 per share, along with warrants for additional shares, aiming to raise approximately $2.25 million to fund clinical trials and working capital [1][2]. Group 1: Private Placement Details - The private placement involves the sale of 1,733,766 shares at $1.30 each, with each share accompanied by a warrant to purchase one additional share at an exercise price of $1.57 [1]. - The warrants are exercisable six months after issuance and have a term of three years [1]. - The expected gross proceeds from the offering are approximately $2.25 million, prior to offering expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital [2]. Group 3: Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5].

Core Insights - MAIA Biotechnology, Inc. has published a manuscript on its Phase 2 THIO-101 clinical trial in the journal Cells, focusing on the management of non-small cell lung cancer (NSCLC) in the context of immunotherapy [1][2] - The company emphasizes the significance of its novel combination strategy using ateganosine with a checkpoint inhibitor, which shows promising results for patients with high unmet medical needs [2] Company Overview - MAIA Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing targeted immunotherapies for cancer, with a focus on first-in-class drugs that aim to improve and extend the lives of cancer patients [4] - The lead program, ateganosine (THIO), is a telomere-targeting agent currently in clinical development for NSCLC patients with telomerase-positive cancer cells [4] Product Details - Ateganosine is a first-in-class investigational agent that targets telomeres, playing a crucial role in cancer cell survival and resistance to therapies [3] - The treatment has shown to induce significant tumor regression in advanced cancer models by activating both innate and adaptive immune responses [3]